modelRopeginterferonAlfa2b
Extends from Pharmacolibrary.Drugs.ATC.L.L03AB15.
Information
| name: | RopeginterferonAlfa2b | |
| ATC code: | L03AB15 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 5.5 | L |
| clearance: | 0.038 | L/h |
| other parameters in model implementation | ||
Ropeginterferon alfa-2b is a mono-pegylated, long-acting interferon-alpha used primarily in the treatment of polycythemia vera and other myeloproliferative neoplasms. It is currently approved for use in certain countries for treating polycythemia vera.
Pharmacokinetics
Pharmacokinetic parameters following subcutaneous administration in adult patients with polycythemia vera.
References
Miyachi, N, et al., & Qin, A (2021). Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. Clinical drug investigation 41(4) 391–404. DOI:10.1007/s40261-021-01026-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33725322
Huang, YW, et al., & Wang, MX (2021). Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. Advances in therapy 38(9) 4756–4770. DOI:10.1007/s12325-021-01863-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/34328630
Lin, HH, et al., & Chen, PJ (2021). Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH open : an open access journal of gastroenterology and hepatology 5(8) 929–940. DOI:10.1002/jgh3.12613 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34386602
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)